Author:
Bozcuk H.,Uslu G.,Peştereli E.,Samur M.,Ozdoğan M.,Karaveli Ş,Sargın F.,Savaş B.
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Gusterson B, Machin L, Gullick W, Gibbs NM, Powles TJ, Price P, McKinna A, Harrison S: Immunohistochemical distribution of c-erbB2 in infiltrating and in situ breast cancer. Int J Cancer 842-845, 1988
2. Berns EM, Foekens JA, Van Stavaren IL, Van Putten WL, de Koning HY, Portengen H, Klijn JG: Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159: 11-18, 1995
3. Hayes DF, Yamauchi H, Stearns V, Brotzman M, Isaacs C, Trock B: Should all breast cancers be tested for c-erb-B2? In: Perry MC (ed) ASCO 2000 Educational Book. Baltimore, American Society of Clinical Oncology, 2000, pp 257-265
4. Savas B, Karaveli S, Uslu G, Basaran L: Significance of P53 and c-erbB-2 for predicting response to CMF treatment in breast carcinoma. Proc ASCO 18: 378 (abstr), 1999
5. Culotta E, Koshland D: Molecules of the year: P53 sweeps through cancer research. Science 262: 1958-1961, 1993
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献